A new report from the North Carolina State Treasurer found North Carolina hospitals use the federal 340B program to profit at the expense of patients, teachers and state employees. Section 340B of the Public Health Service Act requires pharmaceutical manufacturers participating in Medicaid to... Continue Reading
A 2022 tax rule requiring the amortization of research and development expenses has created significant challenges for many life sciences startups and small businesses. Previously, grant money received by these companies and spent on R&D could be deducted immediately in full, but the new rule... Continue Reading
The small red bump on my son's hand looked at first like a bug bite. But when the hand swelled to the point of immobility and we took him to the doctor, the diagnosis was MRSA, an infection from a type of staph bacteria resistant to the family of antibiotics usually prescribed as... Continue Reading
A new study estimates that there would be 237 fewer FDA approvals of new medicines over the next decade and 1.1 million lost jobs if proposals to expand government-mandated drug pricing policies are implemented. The policies include allowing Medicare to set prices for specific drugs five years... Continue Reading
The rarest day on the calendar is the one that does not even occur in every year: February 29. In 2008, this was designated as Rare Disease Day and since then, the last day of February has been an opportunity to draw attention to, honor and support people living with these... Continue Reading
Part D drug price “negotiation” comes at cost of jobs, investment, cures Update: The House passed the Inflation Reduction Act on Friday, Aug. 12. This past weekend, the U.S. Senate passed the Inflation Reduction Act. Included in the law is a provision that gives... Continue Reading
NCBIO stands in solidarity with patient advocates and industry leaders in opposing the Centers for Medicare and Medicaid Services’ draft proposal to restrict coverage for current and future Alzheimer's drugs targeting beta amyloid, a known hallmark of the disease. Restricting coverage is a... Continue Reading
This post originally appeared on the website of the Environmental Paper Network. A serious approach to addressing climate change must include the proactive elimination of unnecessary paper consumption. Paper is an important and useful material that should be produced and consumed in a... Continue Reading
During a busy week in Congress, Democrats included a change to the Orphan Drug Tax Credit that would negatively impact research on rare diseases affecting millions of Americans. The U.S. House of Representatives has several committees marking up the Senate’s $3.5 trillion budget... Continue Reading
BIO: Where things stand with TRIPS waiver It’s been a while since we’ve talked about what’s going on at the WTO. Here’s the latest news—and why the proposed waiver of vaccine IP is still a bad idea. The status: The World Trade Organization is still... Continue Reading
BIO: How the PASTEUR Act would support antibiotic R&D The PASTEUR Act, legislation designed to make research and development of new antibiotics economically viable, was reintroduced in Congress last week with bipartisan support. Here’s what it would do and why it... Continue Reading
Government price fixing for U.S. medicines will cost lives, jobs, innovation Legislation that fixes prices for prescription medicines would limit patients’ access to new treatments while doing nothing to lower prices at the pharmacy counter, according to a new analysis released by... Continue Reading
